Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab  + axitinib vs. ipilimumab + nivolumab

CONCLUSIONS: Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients.PMID:37722984 | DOI:10.1016/j.urolonc.2023.08.009

Source: Urologic Oncology - September 18, 2023 Category: Urology & Nephrology Authors: Neil J Shah Sneha D Sura Reshma Shinde Junxin Shi Puneet Singhal Rodolfo F Perini Robert J Motzer Source Type: research